Back close

2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach

Publication Type : Journal Article

Source : Molecular Diversity. 2022 Nov 10:1–11. doi: 10.1007/s11030-022-10552-z. Epub ahead of print. PMID: 36357813; PMCID: PMC9648999.

Url : https://pubmed.ncbi.nlm.nih.gov/36357813/

Campus : Kochi

School : School of Pharmacy

Department : Pharmacognosy

Year : 2022

Abstract : Nimbamritadi Panchatiktam Kashayam (NPK) is an ayurvedic formulation composed of ingredients with potent anti-viral activities. We studied the interaction energy of 144 phytoconstituents present in NPK against spike receptor-binding domain (RBD) complexed with ACE2 protein (PDB ID: 6LZG) and RNA-dependent RNA polymerase protein (PDB ID: 7BTF) using Biovia Drug Discovery studio. The result indicated that 2,4-hydroxycinnamic acid exerts more significant binding affinities (28.43 kcal/mol) than Umifenovir (21.24 kcal/mol) against spike ACE2. Apigenin exhibited the highest binding affinities (54.63 kcal/mol) compared with Remdesivir (24.52 kcal/mol) against RdRp. An in vitro analysis showed a reduction in the number of lentiviral particles on transfected HEK293T-hACE2 cells as assessed by pseudovirus inhibition assay. At the same time, the tested compounds showed non-toxic up to 100 µg/ml in normal cells by MTT assay. The study highlights the plausible clinical utility of this traditional medicine against SARS CoV2.

Cite this Research Publication : Murali M, Nair B, Vishnu VR, Aneesh TP, Nath LR. 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach. Molecular Diversity. 2022 Nov 10:1–11. doi: 10.1007/s11030-022-10552-z. Epub ahead of print. PMID: 36357813; PMCID: PMC9648999.

Admissions Apply Now